GlycoMimetics, a clinical-stage biotech firm, is making strides in the field of glycobiology-based therapies for cancers and inflammatory diseases in the United States. Notably, the company is developing uproleselan, an E-selectin antagonist that is used alongside chemotherapy to treat acute myeloid leukemia (AML), and is currently undergoing a phase 3 trial to treat relapsed/refractory AML. Additionally, the company is working on multiple other programs including GMI-1687, an antagonist of E-selectin for the treatment of vaso-occlusive crisis, and galectin-3 antagonists, a carbohydrate-binding protein. GlycoMimetics is also in the process of developing GMI-1359, a treatment that targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics was founded in 2003 and is based in Rockville, Maryland.